Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill challenges standard shots in advanced breast cancer fight

NCT ID NCT04214288

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study tested whether a new oral medication called AZD9833 works better than the standard injected treatment (fulvestrant) for women with advanced breast cancer that has stopped responding to previous hormone therapies. It involved 240 post-menopausal women whose cancer had progressed despite prior treatment. Researchers compared how long each treatment kept the cancer from growing and monitored side effects to see if the pill offers advantages over injections.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED ER-POSITIVE HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35205, United States

  • Research Site

    Long Beach, California, 90806, United States

  • Research Site

    Fort Myers, Florida, 33901, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    Lincoln, Nebraska, 68506, United States

  • Research Site

    Canton, Ohio, 44710, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Eagle River, Wisconsin, 54521, United States

  • Research Site

    Brasschaat, 2930, Belgium

  • Research Site

    Charleroi, 6000, Belgium

  • Research Site

    Ghent, 9000, Belgium

  • Research Site

    Haine-Saint-Paul, 7100, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Libramont-Chevigny, 6800, Belgium

  • Research Site

    Namur, 5000, Belgium

  • Research Site

    Greenfield Park, Quebec, J4V 2H1, Canada

  • Research Site

    Montreal, Quebec, H1T 2M4, Canada

  • Research Site

    Montreal, Quebec, H3T 1E2, Canada

  • Research Site

    Paris, 75005, France

  • Research Site

    Vandœuvre-lès-Nancy, 54519, France

  • Research Site

    Batumi, 6000, Georgia

  • Research Site

    Tbilisi, '0112, Georgia

  • Research Site

    Tbilisi, '0159, Georgia

  • Research Site

    Tbilisi, '0186, Georgia

  • Research Site

    Tbilisi, 0159, Georgia

  • Research Site

    Tbilisi, 0186, Georgia

  • Research Site

    Berlin, 10707, Germany

  • Research Site

    Düsseldorf, 40225, Germany

  • Research Site

    Essen, 45136, Germany

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Debrecen, 4032, Hungary

  • Research Site

    Kaposvár, 7400, Hungary

  • Research Site

    Kecskemét, 6000, Hungary

  • Research Site

    Nyíregyháza, 4400, Hungary

  • Research Site

    Pécs, 7624, Hungary

  • Research Site

    Szeged, 6725, Hungary

  • Research Site

    Jerusalem, 91031, Israel

  • Research Site

    Jerusalem, 9112001, Israel

  • Research Site

    Nahariya, 22100, Israel

  • Research Site

    Petah Tikva, 4941492, Israel

  • Research Site

    Bologna, 40138, Italy

  • Research Site

    Catanzaro, 88100, Italy

  • Research Site

    Meldola, 47014, Italy

  • Research Site

    Messina, 98158, Italy

  • Research Site

    Milan, 20141, Italy

  • Research Site

    Milan, 20121, Italy

  • Research Site

    Monza, 20900, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Roma, 00128, Italy

  • Research Site

    Umbria, 5100, Italy

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Lodz, 93-513, Poland

  • Research Site

    Piła, 64-920, Poland

  • Research Site

    Rzeszów, 35-021, Poland

  • Research Site

    Skorzewo, 60-185, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Almada, 2805-267, Portugal

  • Research Site

    Lisbon, 1400-038, Portugal

  • Research Site

    Lisbon, 1449-005, Portugal

  • Research Site

    Lisbon, 1998-018, Portugal

  • Research Site

    Kazan', 420029, Russia

  • Research Site

    Krasnodar, 350040, Russia

  • Research Site

    Kursk, 305035, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Moscow, 123056, Russia

  • Research Site

    Pyatigorsk, 357502, Russia

  • Research Site

    Ryazan, 390011, Russia

  • Research Site

    Saint Petersburg, 197082, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Volgograd, 400138, Russia

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Incheon, 405-760, South Korea

  • Research Site

    Barcelona, 08035, Spain

  • Research Site

    Barcelona, 08190, Spain

  • Research Site

    Madrid, 28050, Spain

  • Research Site

    Seville, 41013, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Cherkasy, 18009, Ukraine

  • Research Site

    Chernivtsі, 58013, Ukraine

  • Research Site

    Kyiv, 03039, Ukraine

  • Research Site

    M. Kyiv, 02094, Ukraine

  • Research Site

    S. Khodosivka, 08173, Ukraine

  • Research Site

    Uzhhorod, 88000, Ukraine

  • Research Site

    Derby, DE22 3NE, United Kingdom

  • Research Site

    Leicester, LE1 5WW, United Kingdom

Conditions

Explore the condition pages connected to this study.

ADVANCED ER-POSITIVE HER2-NEGATIVE BREAST CANCER